文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗中重度特应性皮炎的实验室安全性:三项III期试验结果

Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
PubMed 文献 · Br J Dermatol · 2019-12-01

本文基于LIBERTY AD SOLO 1、SOLO 2和CHRONOS三项随机双盲安慰剂对照III期试验,描述性总结度普利尤单抗治疗中重度特应性皮炎患者的实验室安全性。结果显示,度普利尤单抗组与安慰剂组在常规血液学、血清化学和尿液分析参数上无临床重要变化,支持度普利尤单抗作为中重度特应性皮炎的系统治疗无需常规实验室监测。

要点

  • 度普利尤单抗治疗期间血小板和中性粒细胞较基线轻度下降,但无临床意义。
  • 部分患者出现一过性嗜酸性粒细胞轻度升高,3级嗜酸性粒细胞增多发生率低于1%且无相关不良事件。
  • 所有试验中度普利尤单抗组乳酸脱氢酶水平较基线下降,其他常规实验室参数无临床重要变化。

核心结论

  • 度普利尤单抗治疗中重度特应性皮炎未引起可归因于该药的常规实验室参数临床重要变化。
  • 研究支持度普利尤单抗作为中重度特应性皮炎的系统治疗无需常规实验室监测。

研究设计与样本

  • 三项随机、双盲、安慰剂对照III期试验:LIBERTY AD SOLO 1和SOLO 2(16周)及LIBERTY AD CHRONOS(52周)。
  • SOLO 1和SOLO 2按1:1:1随机分配至度普利尤单抗每周一次、每两周一次或安慰剂组,共1376例患者。
  • CHRONOS按3:1:3随机分配至度普利尤单抗每周一次、每两周一次或安慰剂组,并接受标准化外用糖皮质激素方案,共740例患者。

主要发现

  • 治疗组间基线实验室参数相似。
  • 度普利尤单抗组较安慰剂组血小板和中性粒细胞较基线轻度下降。
  • 部分度普利尤单抗治疗患者出现一过性嗜酸性粒细胞轻度升高,3级嗜酸性粒细胞增多在度普利尤单抗组和安慰剂组均低于1%,且无不良事件与嗜酸性粒细胞增多相关。
  • 所有试验中度普利尤单抗治疗期间乳酸脱氢酶水平较基线下降。
  • 其他血液学、血清化学或尿液分析参数在治疗组间无临床意义变化。

关键数值与推荐

  • 3级嗜酸性粒细胞增多在度普利尤单抗治疗和安慰剂治疗患者中均低于1%。
  • SOLO 1和SOLO 2汇总样本量为1376例,CHRONOS样本量为740例。

临床怎么用

  • 度普利尤单抗治疗中重度特应性皮炎时,常规实验室监测可能无需进行。
  • 治疗期间出现嗜酸性粒细胞一过性轻度升高通常无需特殊处理,但需关注是否伴随相关不良事件。

局限性

  • 实验室结果为描述性总结,未报告统计学比较。
  • 研究未提供关于长期实验室安全性的更多数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for patients aged ≥ 12 years with inadequately controlled, moderate-to-severe atopic dermatitis (AD). Dupilumab trials of up to 52 weeks demonstrated efficacy and a favourable safety profile in patients with moderate-to-severe AD inadequately controlled with topical medications. OBJECTIVES: To further characterize the safety of dupilumab by evaluating clinical laboratory findings from three randomized, double-blinded, placebo-controlled phase III trials (LIBERTY AD SOLO 1 & 2 and LIBERTY AD CHRONOS). METHODS: Patients were randomized 1 : 1 : 1 (SOLO 1 & 2) or 3 : 1 : 3 (CHRONOS) for 16 and 52 weeks, respectively, to dupilumab weekly, every 2 weeks or placebo. CHRONOS patients received a standardized concomitant topical corticosteroid regimen. Laboratory outcomes were summarized descriptively in 1376 patients from SOLO 1 & 2 and 740 from CHRONOS. RESULTS: Treatment groups had similar results in baseline laboratory parameters. Platelets and neutrophils showed mild decreases from baseline in dupilumab vs. placebo groups. Some dupilumab-treated patients had small transient increases in eosinophils. Grade 3 eosinophilia was reported in < 1% of dupilumab-treated and placebo-treated patients; no adverse events were associated with eosinophilia. Lactate dehydrogenase levels decreased from baseline during dupilumab treatment in all trials. No clinically meaningful changes were observed between treatment groups in other haematology, chemistry or urinalysis parameters. CONCLUSIONS: There were no clinically important changes in routine laboratory parameters that could be attributed to dupilumab. This study supports the use of dupilumab as a systemic treatment for moderate-to-severe AD that does not require laboratory monitoring. What's already known about this topic? Long-term treatment of atopic dermatitis (AD) with conventional immunosuppressive agents is limited by the risk of significant side-effects and a need for repeated tests to monitor haematological and/or organ (e.g. liver, kidney) toxicities. Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for the treatment of patients with inadequately controlled, moderate-to-severe AD. In 16-week and 52-week studies, dupilumab demonstrated a positive risk/benefit profile in moderate-to-severe AD. What does this study add? This study is the first comprehensive analysis of dupilumab laboratory safety data of the 16-week SOLO 1 & 2 (pooled N = 1376) and 52-week CHRONOS (N = 740) trials, demonstrating an absence of clinically important changes in haematology, serum chemistry and urinalysis parameters in patients with moderate-to-severe AD treated with dupilumab. Our data support the use of dupilumab as a systemic treatment for the long-term management of moderate-to-severe AD without routine laboratory monitoring in clinical practice.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2019. PMID: 31407311. doi:10.1111/bjd.18434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。